Ramose Laboratories Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 5.60 M
as on 20-05-2024
- Paid Up Capital ₹ 5.50 M
as on 20-05-2024
- Company Age 21 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 37.77%
(FY 2022)
- Profit 104.21%
(FY 2022)
- Ebitda 251.10%
(FY 2022)
- Net Worth 7.32%
(FY 2022)
- Total Assets 30.51%
(FY 2022)
About Ramose Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.60 M and a paid-up capital of Rs 5.50 M, as per Ministry of Corporate Affairs (MCA) records.
Pushpa Thakur, Shabnam Sinha, Abhaya Kumar, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24231DL2002PTC117291
- Company No.
117291
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Oct 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
North Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ramose Laboratories?
Board Members(5)
Financial Performance and Corporate Structure Insights of Ramose Laboratories.
Ramose Laboratories Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 37.77% increase. The company also saw a substantial improvement in profitability, with a 104.21% increase in profit. The company's net worth moved up by a moderate rise of 7.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ramose Laboratories?
In 2021, Ramose Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hecure Agro Plants Private Limited
Active
8 years 3 months Pushpa Thakur and Anil Kumar are mutual person
Shecure Laboratories Private Limited
Active 14 years 7 months Pushpa Thakur and Anil Kumar are mutual person
Hecure Health Care Private Limited
Active 20 years 7 months Pushpa Thakur and Anil Kumar are mutual person
Hecure Products Private Limited
Active 15 years 9 months Pushpa Thakur and Anil Kumar are mutual person
Hecure Developers Private Limited
Active 11 years 10 months Pushpa Thakur and Anil Kumar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ramose Laboratories?
Ramose Laboratories has a workforce of 51 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Mar 21, 2016, Ramose Laboratories has raised a total of ₹ 4 M, with the most recent deal valued at ₹ 4 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
